Literature DB >> 30577904

Assessment of medication for opioid use disorder as delivered within the Vermont hub and spoke system.

Richard Rawson1, Sarah J Cousins2, Michael McCann, Regina Pearce3, Anne Van Donsel4.   

Abstract

Opioid overdose deaths in the United States have risen dramatically in the past decade. In response to this public health crisis, Vermont created an innovative system called the "hub-and-spoke" (H & S) system, initiated in January 2013. The H & S system has 7 regional "hubs" that offer methadone and buprenorphine, as well as intensive support, and 77 local "spokes" (primary care settings) that offer buprenorphine (and naltrexone to a much lesser extent). Questionnaires were administered to 80 participants in the H & S system (stratified by geographic region, treatment site, and gender) and 20 participants with opioid use disorder not currently in treatment. Data included demographics, drug and alcohol use; opioid use; injection use; education/employment; criminal justice involvement; family and relationship functioning; health and healthcare utilization; multiple areas of mental health functioning; opioid overdose; satisfaction with life areas; stigma; and perceived treatment effectiveness. In-treatment group participants reported use and functioning for the 90 days prior to the date of the interview (T2) and, retrospectively, a comparable 90-day period prior to treatment entry (T1). Out-of-treatment group participants were queried about functioning at the time of the interview (T2) and 12 months earlier (T1). Individuals not in treatment showed no meaningful changes in any domain from T1 to T2. Conversely, participants currently in treatment in the H & S system showed large reductions in substance use, overdoses, emergency department visits, police contacts, and family conflict, and improvements in mood and satisfaction with all areas of life, except work/school participation. Additionally, 85% of in-treatment participants reported 90-day abstinence from opioid use compared to 0% of out-of-treatment participants at T2. These findings illustrate that medication for opioid use disorders, as delivered in the H & S system in Vermont, is highly effective for reducing opioid use and overdose and improving functioning in many life domains.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hub and spoke; Medication for opioid use disorders; Opioid use disorder; System of care

Mesh:

Year:  2018        PMID: 30577904     DOI: 10.1016/j.jsat.2018.11.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  12 in total

1.  Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.

Authors:  Richard A Rawson; Traci Rieckmann; Sarah Cousins; Michael McCann; Regina Pearce
Journal:  Prev Med       Date:  2019-07-27       Impact factor: 4.018

2.  The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.

Authors:  Sharon Reif; Mary F Brolin; Maureen T Stewart; Thomas J Fuchs; Elizabeth Speaker; Shayna B Mazel
Journal:  J Subst Abuse Treat       Date:  2019-07-19

3.  Innovations in efforts to expand treatment for opioid use disorder.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2019-08-21       Impact factor: 4.018

4.  Implementation of the hub and spoke model for opioid use disorders in California: Rationale, design and anticipated impact.

Authors:  Gloria M Miele; Lauren Caton; Thomas E Freese; Mark McGovern; Kendall Darfler; Valerie Pearce Antonini; Marlies Perez; Richard Rawson
Journal:  J Subst Abuse Treat       Date:  2019-07-27

Review 5.  The American Opioid Epidemic in Special Populations: Five Examples.

Authors:  Carlos Blanco; Mir M Ali; Aaron Beswick; Karen Drexler; Cheri Hoffman; Christopher M Jones; Tisha R A Wiley; Allan Coukell
Journal:  NAM Perspect       Date:  2020-10-26

6.  Opioid use disorder treatment in rural settings: The primary care perspective.

Authors:  Valerie S Harder; Andrea C Villanti; Sarah H Heil; M Lindsey Smith; Diann E Gaalema; Marjorie C Meyer; Nathaniel H Schafrick; Stacey C Sigmon
Journal:  Prev Med       Date:  2021-08-16       Impact factor: 4.018

7.  Integrating Mental Health and Addiction Treatment Into General Medical Care: The Role of Policy.

Authors:  Emma E McGinty; Gail L Daumit
Journal:  Psychiatr Serv       Date:  2020-06-03       Impact factor: 3.084

8.  Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States.

Authors:  Phillip L Marotta; Kristi L Stringer; Amar D Mandavia; Alissa Davis; Leo Beletsky; Tim Hunt; Dawn Goddard-Eckrich; Elwin Wu; Louisa Gilbert; Nabila El-Bassel
Journal:  J Addict Dis       Date:  2019-12-10

Review 9.  Identification and Management of Opioid Use Disorder in Primary Care: an Update.

Authors:  Joseph H Donroe; Elenore P Bhatraju; Judith I Tsui; E Jennifer Edelman
Journal:  Curr Psychiatry Rep       Date:  2020-04-13       Impact factor: 5.285

10.  Office-Based Methadone Treatment for Opioid Use Disorder and Pharmacy Dispensing: A Scoping Review.

Authors:  Dennis McCarty; Christina Bougatsos; Brian Chan; Kim A Hoffman; Kelsey C Priest; Sara Grusing; Roger Chou
Journal:  Am J Psychiatry       Date:  2021-07-28       Impact factor: 19.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.